The role of mullerian inhibiting substance in female reproduction

Review OA: closed public-domain-us
Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-07 ⓘ

This review examines Mullerian inhibiting substance as a marker of female reproductive function, noting its association with endometriosis, polycystic ovarian syndrome, and in-vitro fertilization outcomes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-09 · read from full text ⓘ

This review examines the biological functions and clinical utility of Mullerian inhibiting substance as a marker for female reproductive health. The authors note that while the hormone mediates follicle recruitment and selection, its exact mechanisms remain unclear, though it is characteristically elevated in polycystic ovarian syndrome and associated with conditions like functional hypothalamic amenorrhea and obesity. The paper highlights its correlation with in-vitro fertilization outcomes but emphasizes the need for assay standardization before widespread clinical implementation. Relevance to endometriosis: listed as one condition where Mullerian inhibiting substance changes have been observed, though the paper's main focus is broader reproductive function and ovulatory disorders.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

PURPOSE OF REVIEW: To review the role of mullerian inhibiting substance in the context of female reproduction. RECENT FINDINGS: Serum and follicular fluid mullerian inhibiting substance can be measured by commercially available enzyme-linked immunosorbent assay kits. Mullerian inhibiting substance is secreted from small antral follicles with minimal fluctuation throughout the menstrual cycle. The exact biological functions of mullerian inhibiting substance are uncertain; however, mullerian inhibiting substance most likely mediates follicle recruitment and selection, and may inhibit aromatase activity. Most data suggests an interaction between follicle-stimulating hormone, and mullerian inhibiting substance although the exact nature of the relationship is unknown. Mullerian inhibiting substance is characteristically elevated in polycystic ovarian syndrome, and may be associated with other features of polycystic ovary syndrome such as insulin resistance, hyperandrogenemia, and the degree of anovulation. Mullerian inhibiting substance changes have also been associated with functional hypothalamic amenorrhea, premature ovarian failure, endometriosis and obesity. Mullerian inhibiting substance has been studied extensively in the context of in-vitro fertilization and has been correlated with several outcome parameters. SUMMARY: Mullerian inhibiting substance is gaining acceptance as a useful marker of female reproductive function, especially with ovulatory disorders and IVF outcomes. Mullerian inhibiting substance offers several advantages to existing screening tests, but establishment of an assay standard should be considered before widespread clinical implementation becomes viable.
Full text 1,786 characters · extracted from oa-doi-fallback · click to expand
The role of mullerian inhibiting substance in female reproduction - Gary S Nakhuda Purpose of review To review the role of mullerian inhibiting substance in the context of female reproduction. Recent findings Serum and follicular fluid mullerian inhibiting substance can be measured by commercially available enzyme-linked immunosorbent assay kits. Mullerian inhibiting substance is secreted from small antral follicles with minimal fluctuation throughout the menstrual cycle. The exact biological functions of mullerian inhibiting substance are uncertain; however, mullerian inhibiting substance most likely mediates follicle recruitment and selection, and may inhibit aromatase activity. Most data suggests an interaction between follicle-stimulating hormone, and mullerian inhibiting substance although the exact nature of the relationship is unknown. Mullerian inhibiting substance is characteristically elevated in polycystic ovarian syndrome, and may be associated with other features of polycystic ovary syndrome such as insulin resistance, hyperandrogenemia, and the degree of anovulation. Mullerian inhibiting substance changes have also been associated with functional hypothalamic amenorrhea, premature ovarian failure, endometriosis and obesity. Mullerian inhibiting substance has been studied extensively in the context of in-vitro fertilization and has been correlated with several outcome parameters. Summary Mullerian inhibiting substance is gaining acceptance as a useful marker of female reproductive function, especially with ovulatory disorders and IVF outcomes. Mullerian inhibiting substance offers several advantages to existing screening tests, but establishment of an assay standard should be considered before widespread clinical implementation becomes viable.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Anti-Mullerian Hormone Infertility, Female Oocytes Anti-Mullerian Hormone Anti-Mullerian Hormone Biomarkers Biomarkers Female Female Fertilization in Vitro Fertilization in Vitro Humans Humans Infertility, Female Infertility, Female Oocytes Oocytes Polycystic Ovary Syndrome Polycystic Ovary Syndrome Polycystic Ovary Syndrome

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-11-04T06:09:08.831786+00:00
pubmed
last seen: 2026-10-08T21:05:19.467219+00:00
unpaywall
last seen: 2026-11-04T06:24:41.714486+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine